Cytotoxicity of ZIF-8@APTES-MS on murine melanoma cells

In this research, ZIF-8 was synthesized and subsequently functionalized by 3-aminopropyltrimethoxysilane (APTES) as a carrier (ZIF-8@APTES) for montelukast sodium (MS). One of the aggressive cancers with a high fatality rate is melanoma. This study aimed to determine the potential cytotoxic effects of montelukast sodium (MS) on the B16F10 murine melanoma cell line as well as the therapeutic effects of MS combined with ZIF-8@APTES as a carrier. B16F10 cells were treated with different doses of ZIF-8@APTES-MS for 24, 48, and 72 h, and then the cytotoxic effect and antioxidant activity of these treatments were studied. Results indicated that after 48 and 72 h, B16F10 cell proliferation was reduced in a dose-dependent manner by MS and/or ZIF-8@APTES-MS. When MS is combined with ZIF-8@APTES, the IC50 concentration is lower than when MS is used alone. Furthermore, receiving 32 μg/ml ZIF-8@APTES-MS after 72 h significantly improved the total antioxidant activity (TAC) of B16F10 cells. In this research, the treatment of melanoma cells with MS and ZIF-8@APTES-MS was investigated.